Ridgewood NJ, in a major blow to the draconian lock down imposed by New Jersey Governor Phil Murphy , the World Health Organization has warned leaders against relying on COVID-19 lockdowns to tackle outbreaks — after previously saying countries should be careful how quickly they reopen.
Ridgewood NJ, according to Johns Hopkins Center for Health Security ,nine months into the COVID-19 pandemic, clinicians are observing more well-defined patterns of long-term health consequences for COVID-19 patients. A commentary published in JAMA describes some of the frequently reported manifestations in recovered patients. Although long-term health effects are more likely to be exhibited by patients with more severe disease (e.g., admitted to an intensive care unit), these effects are also being observed in persons with milder illnesses. General fatigue and dyspnea were the most commonly reported long-term sequelae, in addition to general joint and chest pain.
Ridgewood NJ, according to Johns Hopkins Center for Health Security ,Pharmaceutical manufacturer Eli Lilly submitted an EUA request to the FDA for its monoclonal antibody cocktail as a COVID-19 treatment after clinical trials for the drugs met the target clinical endpoints. Results from a Phase 2 clinical trial indicate that a combination of two of Eli Lilly’s monoclonal antibodies reduced viral load in COVID-19 patients mitigated symptoms and resulted in fewer hospitalizations and emergency department visits. The study included 268 total participants with mild-to-moderate COVID-19 symptoms, 112 of whom received the treatment and 156 who received a placebo. Additionally, a press release issued by the company indicates that no serious adverse events were reported. The company stated that it aims to make 100,000 doses of a single antibody available by the end of October and 1 million by the end of 2020. For the combination therapy, the company hopes to produce 50,000 doses by the end of 2020, and it is collaborating with various external partners to ensure availability for lower-income countries.
Ridgewood NJ, according to Johns Hopkins Center for Health Security, the CDC published new guidance on the potential for airborne transmission of SARS-CoV-2 earlier this week. The updated guidance distinguishes between droplet and airborne transmission (as well as contact transmission); however, it emphasizes that respiratory droplets exist in a spectrum of sizes, ranging from large droplets “that fall out of the air rapidly” to smaller droplets or particles “that can remain suspended for many minutes to hours and travel far from the source.” The guidance also describes aerosols—referring both to smaller droplets and particles and the “clouds of these respiratory droplets in the air”—and clarifies the public health definition of “airborne transmission”—specifically, transmission via “infectious, pathogen-containing, small droplets and particles suspended in the air over long distances and that persist in the air for long times.”
President Trump left Walter Reed National Military Medical Center on Monday evening after spending three days there receiving treatment for the novel coronavirus.
Trump walked out of the hospital just after 6:30 p.m., ignoring questions from reporters while offering a wave and saying, “thank you very much, everybody.” He now returns to the White House where he will continue to be treated for COVID-19.
Ridgewood NJ, jobs , jobs, jobs in the last jobs report before the November election released Friday, September’s very positive jobs numbers actually confirm that we may be experiencing the most dynamic economic recovery in American history.
In September the US Economy added 661,000 jobs despite some of the best efforts by Governor Murphy and Governor Cuomo and tyrannical lock downs.
New Brunswick NJ, according to Johns Hopkins Center for Health Security , Johnson & Johnson (J&J) published (preprint) preliminary findings from the Phase 1/2a clinical trials for its candidate SARS-CoV-2 vaccine (Ad26.COV.S). The studies included nearly 800 participants, who were split into 3 cohorts for the randomized, double-blinded, placebo-controlled study. The first 2 cohorts were made up of 402 healthy adults aged 18-55 years, and the third cohort included 394 healthy adults over the age of 65. The vaccine was given as a single dose or 2 doses administered 56 days apart. The vaccine was generally well tolerated, and the researchers reported 2 serious adverse events. One of the serious adverse events was determined to be unrelated to the vaccine, and the other was a fever that resolved within 12 hours.
Ridgewood NJ, Governor Phil Murphy held Facebook Live chat with Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases Thursday morning.
That look of Rut-Ro when Dr. Fauci tells you during a live TV show that it’s becoming scientifically safe for your State to reopen.
NEW BRUNSWICK NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. These results have been submitted to medRxiv and are due to be published online imminently. Based on these results and following discussions with the U.S. Food and Drug Administration (FDA), ENSEMBLE will enroll up to 60,000 volunteers across three continents and will study the safety and efficacy of a single vaccine dose versus placebo in preventing COVID-19.
Ridgewood NJ, according to Johns Hopkins Center for Health Security as governments and countries press ahead with efforts to develop their own SARS-CoV-2 vaccine—as opposed to large, collaborative, multilateral efforts—”vaccine nationalism” not only creates challenges for the equitable global availability of a future vaccine, it also provides incentive for increased foreign intrusion and “espionage targeting vaccine research and development.” According to analysis published by the Council on Foreign Relations, espionage (including cyber espionage) is not technically prohibited under international law; however, it would violate international law if it were to result in “significant adverse or harmful consequences.” The analysis highlights the “ubiquity of cyber espionage” on SAR-CoV-2 vaccine efforts and the difficulty in “defending against or deterring” it.
People have been laid off from their jobs because of COVID-19 recently. Finding a job these days is a bit challenging. We’re going through a new situation, and we’re gradually adapting to it. Part of adapting is finding new jobs online. It took a pandemic to teach us that we can do most, if not all, types of work from home. The problem lies in the hiring process. How can the recruiters and employers trust us when they’ve only seen us online? Here are our tips on how to make yourself credible when applying for an online job.
Oxford UK, according to Johns Hopkins Center for Health Security, less than a week after suspending Phase 3 clinical trials for its candidate SARS-CoV-2 vaccine due to a serious adverse event, AstraZeneca announced that the trials have resumed in the UK. According to a press release issued by AstraZeneca, the trials resumed after the UK government’s Medicines Health Regulatory Authority (MHRA) evaluated the evidence and determined that it was safe to continue testing the vaccine. The press release states that AstraZeneca and the University of Oxford are not permitted to “disclose further medical information” regarding the adverse event, presumably including the associated safety data reviewed by MHRA or the results of their analysis. It appears that the Phase 3 trials in other countries remain on hold.
Oxford UK, The Phase 3 clinical trial for AstraZeneca’s candidate SARS-CoV-2 vaccine (developed in collaboration with Oxford University) has been paused following the identification of a serious adverse event in one of the participants. Neither AstraZeneca nor Oxford University have yet disclosed details of the adverse event, which reportedly occurred in the UK; however, The New York Times reports that the patient developed transverse myelitis. It has not yet been determined whether the condition was associated with the vaccine. An earlier clinical trial for the AstraZeneca vaccine was also paused following the diagnosis of transverse myelitis in a participant, but the trial resumed after a safety review determined that the condition was not related to the vaccine.
Ridgewood NJ, AstraZeneca COVID19 vaccine expanded into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity.1
The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, and led by AstraZeneca. The NIAID-supported COVID-19 Prevention Network (CoVPN) will participate in the trial.
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “We are pleased that AZD1222 demonstrated safety and immunogenicity across all adult age groups and are proud to be collaborating with BARDA and NIAID to accelerate the development of this vaccine. Should clinical trials demonstrate the vaccine protects against COVID-19 disease and is approved for use, we will work hard to make it globally available in a fair and equitable manner as rapidly as possible.”
